IP Library Granted Patent US 10,278,926
Granted Patent B2
US 10,278,926 · App. 15/525,281 · Granted May 7, 2019

Statin-encapsulated nanoparticle preparation for enhancing stem cell function, stem cell with enhanced function containing statin-encapsulated nanoparticle, and method for producing same

Inventors: Masaaki Ii (Osaka, JP); Yasuhiko Tabata (Kyoto, JP)
Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
A61K9/51A61K9/141A61K9/16A61K31/366A61K35/12A61K35/34A61K45/00A61K47/34A61K47/6931A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,278,926
App. No.
15/525,281
Granted
May 7, 2019
Kind
B2
Abstract

A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

Claims (9)

1. A stem cell with an enhanced function, the stem cell comprising a statin-included nanoparticle for enhancing a function of the stem cell, the statin-included nanoparticle preparation comprising: a statin-included nanoparticle obtained by including statin in a nanoparticle comprising a bioabsorbable polymer, wherein the nanoparticle has a number average particle diameter of less than 1000 nm, wherein the function of the stem cell which is enhanced is at least one selected from the group consisting of a migratory capacity, a proliferation capacity, and a productivity of a neovascularization factor.

2. The stem cell according to claim 1 , wherein the stem cell is an adipose-derived stem cell.

3. The stem cell according to claim 2 , wherein the stem cell is a stem cell for treatment of an ischemic heart disease.

4. A cell preparation for intravenous administration, the cell preparation comprising the stem cell according to claim 1 .

5. A method for manufacturing a stem cell with an enhanced function, the method comprising a step of treating a stem cell with the statin-included nanoparticle according to claim 1 .

6. The method according to claim 5 , wherein in the step of treating a stem cell with the statin-included nanoparticle, the statin-included nanoparticle is added to a medium for incubation of the stem cell to achieve a concentration of 20 μg/mL to 100 μg/mL.

7. The method according to claim 5 , wherein in the step of treating a stem cell with the statin-included nanoparticle, time of the treating with the statin-included nanoparticle is 30 minutes to 2 hours.

8. The method according to claim 5 , wherein the stem cell is an adipose-derived stem cell.

9. The method according to claim 5 , wherein the stem cell is a stem cell for treatment of an ischemic heart disease.

Assignments (2)
CHANGE OF NAME Recorded Feb 22, 2019
From: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
To: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Reel/Frame 048417/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: TABATA, YASUHIKO
To: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
Reel/Frame 043121/0404 →
Priority Claims (1)
JP 2014-228409 · Nov 10, 2014 · national
Continuity (1)
Related Publication 20170319504A1 · Nov 9, 2017